AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

Full data reinforced expectations that AstraZeneca's drug could become a breakthrough treatment for chronic obstructive pulmonary disease (COPD). The therapy is projected to have peak annual sales potential exceeding $5 billion, supporting a positive outlook for AstraZeneca's pipeline and long-term revenue growth.